Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2022- Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET -
-
Jan 20, 2022- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases -
-
Jan 19, 2022Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions